EDL6D, a bioactive peptide phenocopying SHBG-associated metabolic effects: a new preclinical lead compound for treating the metabolic dysfunction-associated fatty liver disease. - Alvarez-Guaita A; Cabrera-Serra J; Perez-Gonzalez B; Salcedo-Allende MT; Fuertes-Rioja L; Ramos-Perez L; Hernandez C; Simó R; Selva DM (Journal of translational medicine, 2026)